Logo image of COCH

ENVOY MEDICAL INC (COCH) Stock Fundamental Analysis

NASDAQ:COCH - Nasdaq - US29415V1098 - Common Stock - Currency: USD

1.37  -0.07 (-4.86%)

Fundamental Rating

0

Overall COCH gets a fundamental rating of 0 out of 10. We evaluated COCH against 188 industry peers in the Health Care Equipment & Supplies industry. COCH may be in some trouble as it scores bad on both profitability and health. COCH does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year COCH has reported negative net income.
In the past year COCH has reported a negative cash flow from operations.
In the past 5 years COCH reported 4 times negative net income.
COCH had a negative operating cash flow in each of the past 5 years.
COCH Yearly Net Income VS EBIT VS OCF VS FCFCOCH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 10M -10M -20M -30M

1.2 Ratios

COCH has a worse Return On Assets (-255.89%) than 95.21% of its industry peers.
Industry RankSector Rank
ROA -255.89%
ROE N/A
ROIC N/A
ROA(3y)-205.35%
ROA(5y)-123.22%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
COCH Yearly ROA, ROE, ROICCOCH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 1K -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for COCH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COCH Yearly Profit, Operating, Gross MarginsCOCH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

0

2. Health

2.1 Basic Checks

COCH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, COCH has more shares outstanding
Compared to 1 year ago, COCH has a worse debt to assets ratio.
COCH Yearly Shares OutstandingCOCH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
COCH Yearly Total Debt VS Total AssetsCOCH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

COCH has an Altman-Z score of -44.78. This is a bad value and indicates that COCH is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -44.78, COCH is doing worse than 94.68% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -44.78
ROIC/WACCN/A
WACC7.34%
COCH Yearly LT Debt VS Equity VS FCFCOCH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

COCH has a Current Ratio of 1.09. This is a normal value and indicates that COCH is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.09, COCH is not doing good in the industry: 87.23% of the companies in the same industry are doing better.
COCH has a Quick Ratio of 1.09. This is a bad value and indicates that COCH is not financially healthy enough and could expect problems in meeting its short term obligations.
COCH has a worse Quick ratio (0.88) than 82.45% of its industry peers.
Industry RankSector Rank
Current Ratio 1.09
Quick Ratio 0.88
COCH Yearly Current Assets VS Current LiabilitesCOCH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for COCH have decreased strongly by -143.90% in the last year.
The Revenue has decreased by -9.40% in the past year.
EPS 1Y (TTM)-143.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.38%
Revenue 1Y (TTM)-9.4%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-22.03%

3.2 Future

The Earnings Per Share is expected to grow by 1.03% on average over the next years.
COCH is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.60% yearly.
EPS Next Y8.3%
EPS Next 2Y1.03%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-14.37%
Revenue Next 2Y-0.6%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

COCH Yearly Revenue VS EstimatesCOCH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 100K 200K 300K
COCH Yearly EPS VS EstimatesCOCH Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for COCH. In the last year negative earnings were reported.
Also next year COCH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
COCH Price Earnings VS Forward Price EarningsCOCH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COCH Per share dataCOCH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.03%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

COCH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENVOY MEDICAL INC

NASDAQ:COCH (6/13/2025, 8:00:01 PM)

1.37

-0.07 (-4.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)N/A N/A
Inst Owners6.44%
Inst Owner Change21.82%
Ins Owners50.1%
Ins Owner Change-27.59%
Market Cap29.22M
Analysts82
Price Target7.27 (430.66%)
Short Float %0.7%
Short Ratio3.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.12
Dividend Growth(5Y)N/A
DP-13.77%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.55%
Min EPS beat(2)-39.48%
Max EPS beat(2)16.38%
EPS beat(4)1
Avg EPS beat(4)-15.16%
Min EPS beat(4)-39.48%
Max EPS beat(4)16.38%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-41.47%
Min Revenue beat(2)-50.59%
Max Revenue beat(2)-32.36%
Revenue beat(4)0
Avg Revenue beat(4)-34.06%
Min Revenue beat(4)-50.59%
Max Revenue beat(4)-19.19%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.93%
PT rev (3m)1.79%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.13%
EPS NY rev (1m)-1.06%
EPS NY rev (3m)-4.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-21.91%
Revenue NY rev (1m)-12.27%
Revenue NY rev (3m)-28.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 137.84
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.39
EYN/A
EPS(NY)-1.39
Fwd EYN/A
FCF(TTM)-0.79
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS0.01
BVpS-1.14
TBVpS-1.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -255.89%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-205.35%
ROA(5y)-123.22%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 493%
Cap/Sales 465.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.09
Quick Ratio 0.88
Altman-Z -44.78
F-Score1
WACC7.34%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-143.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.38%
EPS Next Y8.3%
EPS Next 2Y1.03%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-9.4%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-22.03%
Revenue Next Year-14.37%
Revenue Next 2Y-0.6%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.25%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-313.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-288.87%
OCF growth 3YN/A
OCF growth 5YN/A